Michel Vounatsos (Credit: World Economic Forum/Ciaran McCrickard)
July 5, 2022 07:30 PM EDT
Bioregnum
FDA+

Alzheimer's quick OK, take two: FDA of­fers Bio­gen, Ei­sai a short­cut to a pos­si­ble lecanemab ap­proval

Bio­gen CEO Michel Vounatsos is de­part­ing un­der a dark and wide cloud cre­at­ed by the Aduhelm fi­as­co, which es­sen­tial­ly de­stroyed any hope of any sub­stan­tial …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times